Answers are grounded in this paper and cite their sources.
Urinary I-TAC/CXCL11, CXCL10, IL6 and MCP-1 levels accurately distinguish patients developing ATIN from ATN and healthy individuals and may serve as novel non-invasive biomarkers in this disease.
No takes yet. Share an insight, caveat, or question.
Valenzuela et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: